Non Hodgkin Lymphoma Incidence and Mortality by Year, New York State Excl New York City, 1976-2020

Source: New York State Cancer Registry

Year of Diagnosis/Death Incidence Mortality
Males and Females Males Females Males and Females Males Females
Cases Rate per 100,000 Population 95% CI Cases Rate per 100,000 Males 95% CI Cases Rate per 100,000 Females 95% CI Deaths Rate per 100,000 Population 95% CI Deaths Rate per 100,000 Males 95% CI Deaths Rate per 100,000 Females 95% CI
1976 1,062 11.2 10.5-11.9 552 13.3 12.1-14.5 510 9.6 8.8-10.5 587 6.2 5.7-6.8 309 7.6 6.8-8.6 278 5.2 4.6-5.9
1977 1,155 11.9 11.2-12.6 597 14.3 13.1-15.5 558 10.2 9.4-11.1 642 6.7 6.2-7.2 320 7.8 6.9-8.7 322 5.9 5.2-6.6
1978 1,273 13.0 12.3-13.8 675 15.7 14.5-17.0 598 10.9 10.0-11.8 631 6.6 6.1-7.2 320 8.1 7.1-9.0 311 5.7 5.0-6.3
1979 1,163 11.9 11.2-12.6 586 13.8 12.7-15.1 577 10.4 9.6-11.3 659 6.8 6.3-7.4 358 8.6 7.7-9.6 301 5.4 4.8-6.0
1980 1,246 12.6 11.9-13.4 647 15.0 13.8-16.2 599 10.7 9.9-11.6 664 6.8 6.3-7.3 322 7.7 6.8-8.6 342 6.1 5.5-6.8
1981 1,274 12.8 12.1-13.5 634 14.8 13.7-16.1 640 11.2 10.4-12.2 660 6.7 6.2-7.2 342 8.3 7.4-9.2 318 5.5 4.9-6.2
1982 1,304 13.0 12.3-13.7 684 15.8 14.6-17.1 620 10.9 10.1-11.8 661 6.7 6.2-7.2 344 8.4 7.5-9.4 317 5.4 4.9-6.1
1983 1,417 13.8 13.1-14.6 703 15.9 14.7-17.2 714 12.2 11.3-13.1 704 7.0 6.5-7.5 370 8.7 7.8-9.6 334 5.8 5.2-6.5
1984 1,461 14.4 13.7-15.2 766 17.9 16.6-19.3 695 11.9 11.0-12.8 727 7.2 6.6-7.7 395 9.7 8.7-10.7 332 5.6 5.0-6.2
1985 1,539 15.0 14.2-15.8 816 18.3 17.0-19.6 723 12.3 11.4-13.2 767 7.5 7.0-8.1 403 9.4 8.5-10.4 364 6.1 5.5-6.8
1986 1,604 15.5 14.7-16.3 862 19.5 18.1-20.9 742 12.6 11.7-13.5 811 8.0 7.4-8.5 445 10.6 9.6-11.6 366 6.0 5.4-6.7
1987 1,578 15.1 14.4-15.9 841 18.7 17.4-20.0 737 12.3 11.4-13.3 802 7.8 7.2-8.3 398 9.2 8.3-10.2 404 6.7 6.0-7.4
1988 1,706 16.3 15.6-17.2 880 19.5 18.1-20.9 826 14.0 13.1-15.0 827 8.0 7.4-8.5 419 9.8 8.9-10.8 408 6.7 6.1-7.4
1989 1,789 16.9 16.1-17.7 939 20.3 18.9-21.6 850 14.3 13.3-15.3 856 8.1 7.6-8.7 459 10.4 9.5-11.5 397 6.4 5.8-7.1
1990 1,886 17.6 16.8-18.4 1,009 21.6 20.3-23.1 877 14.3 13.4-15.3 897 8.5 7.9-9.1 460 10.5 9.5-11.6 437 7.0 6.3-7.7
1991 1,869 17.3 16.6-18.1 981 21.4 20.0-22.8 888 14.5 13.6-15.5 905 8.4 7.8-8.9 473 10.8 9.8-11.8 432 6.7 6.1-7.4
1992 1,866 17.1 16.4-18.0 992 20.9 19.6-22.3 874 14.1 13.2-15.1 955 8.8 8.2-9.4 489 11.0 10.0-12.1 466 7.3 6.6-8.0
1993 1,989 18.2 17.4-19.0 1,053 21.8 20.5-23.2 936 15.1 14.1-16.1 893 8.1 7.6-8.6 443 9.7 8.8-10.7 450 6.9 6.2-7.5
1994 2,082 18.8 18.0-19.6 1,124 23.3 21.9-24.7 958 15.1 14.2-16.1 994 8.9 8.4-9.5 513 11.3 10.3-12.3 481 7.3 6.7-8.0
1995 2,103 18.9 18.1-19.7 1,107 22.9 21.6-24.3 996 15.8 14.8-16.8 1,021 9.1 8.6-9.7 532 11.7 10.7-12.7 489 7.4 6.7-8.1
1996 2,288 20.4 19.5-21.2 1,209 24.7 23.3-26.2 1,079 17.0 16.0-18.0 1,027 9.1 8.5-9.7 531 11.5 10.5-12.5 496 7.4 6.8-8.1
1997 2,323 20.5 19.7-21.3 1,202 24.3 22.9-25.7 1,121 17.5 16.5-18.6 1,066 9.3 8.8-9.9 538 11.3 10.3-12.3 528 7.9 7.2-8.6
1998 2,387 20.9 20.0-21.7 1,212 24.2 22.9-25.6 1,175 18.2 17.2-19.3 990 8.5 8.0-9.1 479 9.9 9.0-10.8 511 7.5 6.9-8.2
1999 2,437 21.1 20.2-21.9 1,229 24.3 22.9-25.7 1,208 18.6 17.5-19.7 952 8.1 7.6-8.7 465 9.7 8.8-10.7 487 7.1 6.5-7.8
2000 2,441 20.8 20.0-21.7 1,250 24.5 23.1-25.9 1,191 18.0 17.0-19.1 1,014 8.5 8.0-9.1 510 10.4 9.5-11.4 504 7.2 6.6-7.9
2001 2,448 20.7 19.9-21.5 1,251 24.3 22.9-25.7 1,197 18.0 16.9-19.0 927 7.7 7.2-8.2 499 9.9 9.1-10.8 428 6.0 5.4-6.6
2002 2,520 21.1 20.3-21.9 1,336 25.5 24.2-27.0 1,184 17.7 16.7-18.8 937 7.7 7.2-8.2 505 10.1 9.2-11.0 432 6.1 5.5-6.7
2003 2,616 21.6 20.8-22.5 1,332 25.0 23.7-26.4 1,284 18.9 17.9-20.0 842 6.8 6.4-7.3 426 8.5 7.7-9.4 416 5.7 5.1-6.3
2004 2,661 21.8 21.0-22.7 1,424 26.5 25.1-27.9 1,237 18.3 17.3-19.3 839 6.7 6.3-7.2 410 7.9 7.2-8.7 429 5.8 5.2-6.3
2005 2,743 22.3 21.4-23.1 1,475 27.1 25.7-28.5 1,268 18.4 17.4-19.5 807 6.4 5.9-6.8 430 8.3 7.5-9.1 377 5.0 4.5-5.6
2006 2,874 23.1 22.3-24.0 1,482 26.9 25.6-28.4 1,392 20.0 18.9-21.1 893 7.0 6.6-7.5 454 8.5 7.7-9.4 439 5.8 5.2-6.3
2007 2,888 22.9 22.0-23.7 1,553 27.8 26.4-29.2 1,335 19.1 18.0-20.2 794 6.1 5.7-6.5 437 8.1 7.3-8.9 357 4.7 4.2-5.2
2008 2,934 23.1 22.3-24.0 1,564 27.7 26.3-29.1 1,370 19.5 18.5-20.6 861 6.6 6.1-7.0 450 8.2 7.5-9.0 411 5.4 4.9-6.0
2009 2,987 23.1 22.3-24.0 1,615 28.0 26.6-29.4 1,372 19.3 18.3-20.4 818 6.2 5.7-6.6 459 8.2 7.5-9.0 359 4.7 4.2-5.2
2010 3,007 22.9 22.1-23.7 1,596 27.3 26.0-28.7 1,411 19.3 18.2-20.3 855 6.3 5.9-6.8 450 7.9 7.2-8.7 405 5.2 4.7-5.8
2011 3,001 22.7 21.9-23.6 1,659 28.0 26.6-29.4 1,342 18.6 17.6-19.6 841 6.2 5.8-6.6 451 7.8 7.1-8.6 390 5.0 4.5-5.5
2012 2,996 22.2 21.4-23.1 1,615 26.9 25.6-28.3 1,381 18.6 17.6-19.6 803 5.9 5.5-6.3 440 7.6 6.9-8.4 363 4.5 4.0-5.0
2013 3,069 22.6 21.8-23.4 1,670 27.4 26.0-28.7 1,399 18.8 17.8-19.8 743 5.3 4.9-5.7 401 6.7 6.1-7.5 342 4.1 3.7-4.6
2014 3,193 23.1 22.2-23.9 1,767 28.5 27.2-29.9 1,426 18.6 17.7-19.7 810 5.7 5.3-6.1 450 7.5 6.8-8.2 360 4.3 3.8-4.8
2015 3,212 23.1 22.2-23.9 1,762 27.9 26.5-29.2 1,450 19.2 18.2-20.3 793 5.5 5.1-5.9 442 7.2 6.5-7.9 351 4.2 3.8-4.7
2016 3,253 23.1 22.3-24.0 1,718 26.9 25.6-28.2 1,535 20.2 19.1-21.2 809 5.5 5.1-5.9 438 7.0 6.3-7.7 371 4.4 4.0-4.9
2017 3,209 22.4 21.6-23.2 1,768 27.2 25.9-28.5 1,441 18.6 17.6-19.6 845 5.7 5.3-6.1 487 7.6 7.0-8.4 358 4.1 3.7-4.6
2018 3,137 21.8 21.0-22.6 1,664 25.2 24.0-26.5 1,473 19.1 18.1-20.1 728 4.8 4.5-5.2 418 6.5 5.9-7.2 310 3.7 3.2-4.1
2019 3,252 22.2 21.4-23.0 1,790 26.7 25.5-28.1 1,462 18.5 17.5-19.5 742 4.8 4.5-5.2 404 6.1 5.5-6.8 338 3.9 3.5-4.3
2020 2,949 20.0 19.3-20.8 1,613 23.9 22.7-25.2 1,336 16.9 16.0-17.9 705 4.6 4.2-4.9 372 5.6 5.0-6.2 333 3.8 3.4-4.2

Notes

  • Incidence data are provisional, November 2022.
  • Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals.
  • Rates based on fewer than 20 cases or deaths per year are unstable and should be used with caution.
  • Cancer diagnoses trends in 2020 may have been affected by the coronavirus disease 19 (COVID-19) pandemic.
  • The data in this table are not identical to the data in the corresponding 2016-2020 incidence table. See the rationale in 'Considerations When Comparing Cancer Statistics Over Time'.